Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · Real-Time Price · USD
6.69
-0.03 (-0.45%)
At close: Feb 21, 2025, 4:00 PM
6.80
+0.11 (1.64%)
After-hours: Feb 21, 2025, 4:33 PM EST
Aldeyra Therapeutics Employees
Aldeyra Therapeutics had 10 employees as of December 31, 2023. The number of employees decreased by 5 or -33.33% compared to the previous year.
Employees
10
Change (1Y)
-5
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$4,479,564
Market Cap
398.39M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
ALDX News
- 18 days ago - Aldeyra Therapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference - Business Wire
- 2 months ago - Aldeyra Therapeutics: Key Inflection Point Ahead - Seeking Alpha
- 2 months ago - Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference - Business Wire
- 3 months ago - Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement - Business Wire
- 3 months ago - Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference - Business Wire
- 3 months ago - Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects - Seeking Alpha
- 4 months ago - Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting - Business Wire
- 5 months ago - Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease - Business Wire